Workflow
圣达生物: 浙江圣达生物药业股份有限公司第四届董事会第十九次会议决议公告

Group 1 - The board of directors of Zhejiang Shengda Biological Pharmaceutical Co., Ltd. held its 19th meeting on August 22, 2025, with all 9 directors present, confirming the legality and validity of the meeting procedures [1][2] - The board approved the 2025 semi-annual report and summary, which had been reviewed by the audit committee [2] - The board also approved the proposal for the appointment of the auditing institution for the year 2025, which will be submitted to the shareholders' meeting for further approval [2][3] Group 2 - The board reviewed and approved the special report on the storage and use of raised funds for the first half of 2025, with unanimous support from all directors [2] - A proposal to convene the third extraordinary general meeting of shareholders in 2025 was also approved, with all directors voting in favor [3]